Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 620 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
- Banner Children's at Desert — Mesa, Arizona
+ 182 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Locations: - Cedars-Sinai Medical Center — Los Angeles, California
- Kaiser Permanente - Panorama City — Panorama City, California
- Jupiter Medical Center — Jupiter, Florida
+ 179 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Locations: - University of Alabama at Birmingham — Birmingham, Alabama
- Cancer Treatment Center of America Phoenix — Goodyear, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
+ 50 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Locations: - USA Mitchell Cancer Institute ( Site 0014) — Mobile, Alabama
- Banner MD Anderson Cancer Center ( Site 0059) — Gilbert, Arizona
- Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051) — Phoenix, Arizona
+ 43 more sites in the U.S.
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Locations: - Phoenix Children's Hospital — Phoenix, Arizona
- Arkansas Children's Hospital — Little Rock, Arkansas
- MemorialCare Miller Children's and Women's Hospital Long Beach — Long Beach, California
+ 42 more sites in the U.S.
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- University of California, Fresno — Clovis, California
- University of California, San Diego — La Jolla, California
+ 39 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Locations: - Uci Health Laguna Hills — Laguna Hills, California
- Chao Family Comprehensive Cancer Center — Orange, California
- Stanford Cancer Institute — Palo Alto, California
+ 35 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound foun…
Sponsor: Children's Oncology Group
NCT ID: NCT07022678
Locations: - Arkansas Children's Hospital — Little Rock, Arkansas
- Valley Children's Hospital — Madera, California
- Kaiser Permanente-Oakland — Oakland, California
+ 25 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT04256317
Locations: - Keck School of Medicine of USC — Los Angeles, California
- UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange, California
- Yale University — New Haven, Connecticut
+ 21 more sites in the U.S.
Phase 3 Recruiting Industry
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Sponsor: Priothera SAS
NCT ID: NCT05429632
Locations: - University of Alabama Hospital (UAB Hospital) — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- City of Hope Comprehensive Cancer Center - Duarte — Duarte, California
+ 18 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Locations: - Pacific Cancer Medical Center, Inc — Anaheim, California
- TOI Clinical Research — Cerritos, California
- Stanford School of Medicine-Cancer Clinical Trials Office — Palo Alto, California
+ 16 more sites in the U.S.